Related Experiment Video

Updated: Jul 16, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

G-coupled protein receptors and breast cancer progression: potential drug targets

Marcelo Taborga1, Kelly E Corcoran, Neil Fernandes

  • 1Graduate School of Biomedical Sciences, UMDNJ, USA.

Mini Reviews in Medicinal Chemistry
|March 10, 2007
PubMed

Insights

Novel G-protein coupled receptors, including neurokinin-1, neurokinin-2, and chemokine receptor 4, offer new therapeutic targets for breast cancer treatment, especially for metastatic and receptor-negative disease. These targets address limitations of current therapies in eradicating dormant cancer stem cells.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Breast cancer is a leading cause of death, with bone marrow metastasis complicating prognosis and treatment.
  • Current therapies targeting hormonal receptors (HER2, ER) and chemotherapy have limited success against quiescent cancer stem cells and metastatic disease.
  • Receptor-negative and metastatic breast cancers lack effective targeted treatments.

Purpose of the Study:

  • To review the role of G-protein coupled receptors (GPCRs) as novel therapeutic targets in breast cancer.
  • To highlight GPCRs, specifically neurokinin-1 (NK1), neurokinin-2 (NK2), and chemokine receptor 4 (CXCR4), for their potential in treating advanced breast cancer.
  • To address the unmet need for targeted therapies against dormant cancer stem cells and metastatic breast cancer.

Main Methods:

  • Literature review of existing studies on breast cancer metastasis and therapeutic targets.
  • Analysis of the role of specific GPCRs (NK1, NK2, CXCR4) in breast cancer progression and stem cell dormancy.
  • Discussion of the potential of targeting these GPCRs for novel therapeutic strategies.

Main Results:

  • GPCRs, including NK1, NK2, and CXCR4, are implicated in breast cancer cell survival, migration, and bone marrow metastasis.
  • These receptors represent potential targets for therapies aimed at eradicating dormant cancer stem cells responsible for relapse.
  • Targeting GPCRs may offer a new avenue for treating aggressive, receptor-negative, and metastatic breast cancer.

Conclusions:

  • G-protein coupled receptors present promising novel targets for breast cancer therapy.
  • Targeting NK1, NK2, and CXCR4 could overcome limitations of current treatments, particularly for metastatic and receptor-negative disease.
  • Further research into GPCR-targeted therapies is warranted to improve outcomes for advanced breast cancer patients.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical, 7TM, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...